The UK and US have announced a important bilateral deal that will guarantee no tariffs on British drug products being sold in the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the NHS. This commitment guarantees that duties on these key goods will be held at zero for a period of 36 months.
This agreement comes after recent statements to hike tariffs on patented drug imports, with increases discussed up to one hundred percent.
"This arrangement with the United Kingdom reinforces the international landscape for cutting-edge drugs and brings much-needed equity to American-British drug exports," a release noted.
Trade Impact
Pharmaceuticals represent one of the Britain's most significant export categories to the United States, which is by far the largest market for major UK drugmakers.
Export figures show that in the one-year period leading up to last September, the UK exported medicines totaling billions to the US. This amount represented a significant portion of total UK exports in that period.
"This agreement secures employment, boosts capital expenditure and paves the way for the UK to emerge as a worldwide center for medical research," a government official stated.
Specific British Pledges
The agreement entails several specific pledges from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to double overall public funding on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The sum drug companies must return to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates topped twenty percent.
Broader Context
The deal follows a protracted tension between the drug companies and the British authorities over drug pricing and approval rates.
This friction were heightened by assertions that US consumers were charged several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or abandoned, while major investments have been announced toward US facilities.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its spending on drugs had declined as a share of its total funding over the past decade.
